Momelotinib in VEXAS syndrome: a preliminary report evaluation of safety and effectiveness (ACR Convergence 2026) - Sep 8, 2026 - Abstract #684; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Janus kinase (JAK) inhibitors, particularly ruxolitinib (RUXO), have proven their efficacy in VEXAS syndrome. Our study represents one of the first case series evaluating MMB in VEXAS syndrome. Treatment was associated with an overall improvement in Hb levels and a stabilization in the daily dose of GCs, despite slight fluctuations in CRP values. Notably, ddPCR levels halved from baseline at six months."
Clinical • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Myelodysplastic Syndrome • Myelofibrosis • ACVR1 • CRP • JAK1 • JAK2
|
|
Corrado Campochiaro1; Costanza Piccolo2; Alessandro Tomelleri3; Gregorio Maria Bergonzi4; Enrico Cozzo5; Carmelo Gurnari6; Francesca Romano7; Rossella Puzziferri8; Anna Baldisserotto8; Luca Vago5; Fabio Ciceri5; Marco Matucci-Cerinic9; Elisa Diral5; Lorenzo Dagna10
|